Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?-Reference-Cited by-同舟云学术

Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?

Published:2020-06 Issue: Volume:86 Page:102023
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Martini Giulia,Ciardiello Davide,Vitiello Pietro Paolo,Napolitano Stefania,Cardone Claudia,Cuomo Antonio,Troiani Teresa,Ciardiello Fortunato,Martinelli Erika

Funder

Regione Campania Cancer Research Campaign I-Cure

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference116 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Drug therapy: EGFR antagonists in cancer treatment;Ciardiello;N Engl J Med,2008

3. Hallmarks of cancer: The next generation;Hanahan;Cell,2011

4. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor;Saltz;J Clin Oncol,2004

5. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer;Van Cutsem;J Clin Oncol,2007

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the secrets: Evolution of resistance mediated by membrane proteins;Drug Resistance Updates;2024-11

2. SIRT1: a novel regulator in colorectal cancer;Biomedicine & Pharmacotherapy;2024-09

3. Circulating tumour DNA analysis and new uses of anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer;Medical alphabet;2024-05-10

4. Unveiling the hub genes in the SIGLECs family in colon adenocarcinoma with machine learning;Frontiers in Genetics;2024-04-08

5. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment;International Immunopharmacology;2024-04